The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Sep. 27, 2005
Filed:
Jun. 05, 1998
Patricia A. Billing-medel, Grayslake, IL (US);
Maurice Cohen, Munster, IN (US);
Tracey L. Colpitts, Round Lake, IL (US);
Paula N. Friedman, Buffalo Grove, IL (US);
Julian Gordon, Lake Bluff, IL (US);
Edward N. Granados, Vernon Hills, IL (US);
Steven C. Hodges, Buffalo Grove, IL (US);
Michael R. Klass, Carlsbad, CA (US);
Jon D. Kratochvil, St. Louis, MO (US);
Lisa Roberts-rapp, Gurnee, IL (US);
John C. Russell, Pleasant Prairie, WI (US);
Stephen D. Stroupe, Libertyville, IL (US);
Hong Yu, Long Grove, IL (US);
Patricia A. Billing-Medel, Grayslake, IL (US);
Maurice Cohen, Munster, IN (US);
Tracey L. Colpitts, Round Lake, IL (US);
Paula N. Friedman, Buffalo Grove, IL (US);
Julian Gordon, Lake Bluff, IL (US);
Edward N. Granados, Vernon Hills, IL (US);
Steven C. Hodges, Buffalo Grove, IL (US);
Michael R. Klass, Carlsbad, CA (US);
Jon D. Kratochvil, St. Louis, MO (US);
Lisa Roberts-Rapp, Gurnee, IL (US);
John C. Russell, Pleasant Prairie, WI (US);
Stephen D. Stroupe, Libertyville, IL (US);
Hong Yu, Long Grove, IL (US);
Abbott Laboratories, Abbott Park, IL (US);
Abstract
A set of contiguous and partially overlapping cDNA sequences and polypeptides encoded thereby, designated as BL172 and transcribed from urinary tract tissue, is described. These sequences are useful for the detecting, diagnosing, staging, monitoring, prognosticating, in vivo imaging, preventing or treating, or determining the predisposition of an individual to diseases and conditions of the urinary tract, such as urinary tract cancer. Also provided are antibodies which specifically bind to BL172-encoded polypeptide or protein, and agonists or inhibitors which prevent action of the tissue-specific BL172 polypeptide, which molecules are useful for the therapeutic treatment of urinary tract diseases, tumors or metastases.